Capstone Investment Advisors
STOK icon

Capstone Investment Advisors’s Stoke Therapeutics STOK Stock Holding History

Capstone Investment Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$314K Sell
9,584
-2,646
-22% -$84.9K ﹤0.01% 1435
2026
Q1 		$398K Buy
+12,230
New +$401K ﹤0.01% 1250

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capstone Investment Advisors's STOK Position: Q2 2026 in Review

Capstone Investment Advisors reduced its Stoke Therapeutics (STOK) stake by 22% in Q2 2026, selling an estimated $84.9K and leaving 9,584 shares worth $314K. The position accounts for ﹤0.01% of the portfolio, ranked #1435.

Capstone Investment Advisors first reported a position in STOK in Q1 2026 and has held it in 2 quarters since. The position peaked at $398K in Q1 2026. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Capstone Investment Advisors held 9,584 shares of Stoke Therapeutics worth $314K as of Q2 2026.
  • Capstone Investment Advisors sold 2,646 Stoke Therapeutics shares in Q2 2026, an estimated $84.9K.
  • Stoke Therapeutics made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1435 holding.
  • Capstone Investment Advisors first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Capstone Investment Advisors's Stoke Therapeutics position peaked at $398K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.